Department
Health Professions & Wellness
Document Type
Article
Publication Date
2025
Abstract
Ewing sarcoma (ES) is a high-grade bone and soft tissue tumor in adolescents and young adults. Cytotoxic chemotherapy does not improve prognosis, especially for advanced ES patients who have a 5-year survival of 30% or less [1, 2]. Molecular targeted therapy emerges as a promising strategy to battle ES, given its unique driver mutations resulting from the fusion of the EWS and one of the ETS genes, but the feasibility of directly blocking EWS-ETS function has not yet been established [3]. To search for new therapeutic targets, we began with an analysis of the Cancer Dependency Map (DepMap) datasets that contain data from the CRISPR loss-of-function screens in 25 human ES cell lines (https://doi.org/10.25452/figshare.plus.27993248.v1). Further assessment of the lethal knockouts (indicated by gene effect score less than −1) revealed 308 common genes shared among all ES strains tested (Figure S1A and Table S1). These genes, when subjected to gene ontology (GO) analysis, showed the most significant relationship with ribosome biogenesis (Figure 1A), making this cellular process a candidate therapeutic target in ES.
Recommended Citation
Bruce, A., Anchondo, G., Carter, R., Guerrero Pacheco, S., Kambala, H. S., Cortez, E., Parker, K., & Su, L. (2025). Targeting RNA Polymerase I in Ewing Sarcoma Treatment. Cancer Science. 0, 1-3. https://doi.org/10.1111/cas.70047
Publication/Presentation Information
Cancer Science, 0, March 2025, 1-3.